Samarth Kulkarni - 18 Feb 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Samarth Kulkarni
Issuer symbol: CRSP
Transactions as of: 18 Feb 2026
Net transactions value: -$366,325
Form type: 4
Filing time: 20 Feb 2026, 17:36:52 UTC
Previous filing: 22 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kulkarni Samarth	Chief Executive Officer, Director	C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Samarth Kulkarni	20 Feb 2026	0001682019

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRSP	Common Shares	Options Exercise		+13,250	+6%		233,073	18 Feb 2026	Direct	F1, F2
transaction	CRSP	Common Shares	Sale	$366,325	-6,967	-3%	$52.58	226,106	19 Feb 2026	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Restricted Stock Units	Options Exercise		-13,250	-100%		0	18 Feb 2026	Common Shares	13,250		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2	Reflects 85,622 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person.
F3	Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F4	This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.